Skip to main content

Table 3 Summary of responders to immunotherapies in this study. Percentage is the number of responders out of the total number treated with that particular histologic subtype

From: Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Sarcoma type Best response # responders total %
Alveolar soft part Partial response 2 4 50.0%
Alveolar soft part Stable disease 2 4 50.0%
GIST Stable disease 3 9 33.3%
Well-diff liposarcoma Stable disease 1 2 50.0%
De-diff liposarcoma Stable disease 2 5 40.0%
Leiomyosarcoma Stable disease 2 12 16.7%
Osteosarcoma Stable disease 1 5 20.0%